Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into how the treatment and management of cytokine release syndrome (CRS) has improved in recent years, and further discusses other long-term CAR-related toxicities, including cytopenias and immunoglobulin deficiency. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.